MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) after the closing bid price of the Company’s common stock was $1.00 per share or greate ...

PALM BEACH, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous industry reports agree that the global drone markets will continue to thrive and exceed present revenues in the coming years. According to a report from Research and Markets, the global drones market size reached a value of USD $38.25 billion in 2023 (and USD $48.62 Billions in 2024). Aided by the increasing adoption of drones across various sectors, including agriculture, defense, logistics, and entertainment, the ...

Company Overview - Windward Bio is a clinical-stage drug development company focused on improving outcomes for advanced immunological diseases, with an initial focus on severe respiratory conditions [8] - The company is led by a highly experienced team of biopharmaceutical executives with a track record of 15+ product launches, 2 Nasdaq IPOs, and 2 major sales (Therachon to Pfizer for $810M and VectivBio to Ironwood for $1.2B) [3] - Windward Bio has secured $200M in Series A financing led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with co-investment from SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners [1] Product Pipeline - WIN378 is a potential best-in-class, long-acting monoclonal antibody targeting the TSLP ligand, with dosing every 6 months, currently preparing for Phase 2 trials in severe asthma with initial clinical readouts expected in 2026 [2][6] - The company is building a discovery pipeline of long-acting bispecifics leveraging validated targets and synergistic biology, with Series A financing supporting the advancement of 2 undisclosed programs through IND-enabling studies [4][7] - WIN378 has been engineered for extended half-life and effector silencing, administered subcutaneously, and has shown benefits in inflammatory phenotypes for asthma and COPD [6] Strategic Partnerships - Windward Bio has licensed WIN378 from Kelun-Biotech and Harbour BioMed for global rights, excluding China and select smaller Asian markets [1] - Harbour BioMed, a global biopharmaceutical company, focuses on novel antibody therapeutics in immunology and oncology, utilizing proprietary antibody technology platforms like Harbour Mice and HBICE [9][10] - Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, focuses on innovative biological and small molecule drugs, with over 30 ongoing projects, including a leading proprietary ADC platform, OptiDC™ [12] Market Opportunity - WIN378 targets approximately 5 million advanced, uncontrolled patients with severe asthma and COPD in the US, Europe, and Japan [2] - The company aims to address unmet needs in immunological diseases through its lead program and bispecific pipeline, leveraging validated targets and synergistic biology [7][8]

CHENNAI, India, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Limited (NASDAQ: SIFY), India’s leading ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the Third Quarter ended December 31, 2024 on Friday, January 17, 2025 before the market opens. In conjunction with the announcement, Sify will host a conference call at 8:30 AM ET with Mr. Raju Vegesn ...

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE). The investigation concerns whether Dave Inc. and certain of its officers and/or directors have engaged in securities fraud.    PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFO ...

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE). The investigation concerns whether Dave Inc. and certain of its officers and/or directors have engaged in securities fraud. PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORM ...

SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, announced today new partnerships with Carlson Distributing, Bison Beverage, George's Distributing, and Craig Stein Beverage to service Smith’s Food & Drug locations across the western United States. Smith’s Food & Drug, a regional grocery chain with locations in Utah, Nevada, New Mexico, Arizona, Montana, Idaho, and Wyoming, is a subsi ...

NEW YORK, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Hola Prime launched One-Hour Payment service to solve the biggest problem of Prop Trading. Delays in payouts have long been a source of frustration for traders in the prop trading industry. Many firms require traders to wait for days or even weeks, creating uncertainty and eroding trust. Hola Prime has turned this challenge into an opportunity to lead with innovation. "Waiting for payouts can be incredibly stressful for traders, especially when they've worked ...

Event Participation - Rigetti CEO Dr Subodh Kulkarni will participate in a fireside chat at the 27th Annual Needham Growth Conference on January 14 2025 [1] - The event will be webcast live from 11:45 am to 12:25 pm ET and a replay will be available for 180 days [1] Company Overview - Rigetti is a pioneer in full-stack quantum computing operating quantum computers over the cloud since 2017 [2] - The company serves global enterprise government and research clients through its Rigetti Quantum Cloud Services platform [2] - Rigetti began selling on-premises quantum computing systems with qubit counts between 24 and 84 qubits in 2021 [2] - The company introduced the 9-qubit Novera™ QPU in 2023 designed to plug into customer's existing cryogenic and control systems [2] - Rigetti has developed the industry's first multi-chip quantum processor for scalable quantum computing systems [2] - The company designs and manufactures its chips in-house at Fab-1 the industry's first dedicated and integrated quantum device manufacturing facility [2] Media Contact - Rigetti Computing media contact is press@rigetti com [3]

Algeria’s honey scene blends tradition and innovation, with passionate buyers seeking exclusive floral sources. Beekeepers embrace hive-monitoring technology to withstand climate extremes. Culinary integration spans cafés to luxury hotels, showcasing honey’s versatility and hinting at sustained market momentum.New Delhi, Jan. 10, 2025 (GLOBE NEWSWIRE) -- According to the latest study from Astute Analytica, the Algeria honey market is projected to attain a market valuation of US$ 95.63 million by 2033 from U ...